NCT00097890View on ClinicalTrials.gov

Replagal Enzyme Replacement Therapy for Adults With Fabry Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

December 31, 2005

Conditions
Fabry Disease
Interventions
DRUG

Replagal (Agalsidase Alfa)

DRUG

Replagal

Trial Locations (1)

20892

National Institute of Neurological Disorders and Stroke (NINDS), Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00097890 - Replagal Enzyme Replacement Therapy for Adults With Fabry Disease | Biotech Hunter | Biotech Hunter